Kyoko Ohno-Matsui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyoko Ohno-Matsui has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Manabu Mochizuki
Tokyo Medical and Dental University
8 shared publicationsTakashi Tokoro
7 shared publicationsTakeshi Yoshida
7 shared publicationsAriko Kojima
5 shared publicationsKenjiro Yasuzumi
5 shared publicationsNoriaki Shimada
5 shared publications
Latest Publications
- Top Cited Papers
- 1 May 2019
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 70, 99-109
Posterior staphyloma in pathologic myopia
- 1 May 2019
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 70, 99-109
Top Cited PapersPosterior staphyloma in pathologic myopia
- Open Access
- 29 August 2018
- Published by Springer Nature in Eye
- Vol. 32 (12) , 1871-1878
Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
Objectives The aim of this study was to obtain real-world clinical data on the safety and efficacy of ranibizumab treatment for myopic choroidal neovascularization (CNV) due to pathologic myopia. Methods This was a prospective, observational, post-marketing surveillance study in ranibizumab-naive Japanese patients with myopic CNV. Patients who initiated ranibizumab treatment were registered and prospectively observed over 12 months. Safety endpoints were the incidence of ocular and non-ocular adverse drug reactions (ADRs) and serious adverse events (SAEs). The efficacy endpoint included the average change in best-corrected visual acuity (BCVA) in logarithm of the minimal angle of resolution (logMAR) units (logMAR BCVA) from baseline to the last observation. Results Three hundred and eighteen patients were included in the safety analysis population. Of these 79.9% were female and the mean age was 65.5 years. The incidences of SAEs and ADRs were 0.6 and 0.3%, respectively. A total of 268 patients (84.0%) completed the 12-month study period. The mean (±SD) and median number of ranibizumab injections were 2.0 ± 1.5 and 1.0 during the 12-month study period, respectively. The number of ranibizumab injections received was one in 52.2% of patients and less than or equal to three in 89.2%. The mean change in logMAR BCVA from baseline to month 12 was −0.193, and the mean logMAR BCVA improved from 0.517 to 0.319 between baseline and month 12. Conclusions This study showed that ranibizumab is generally well tolerated, and that a minimum number of injections were necessary to produce a therapeutic effect in Japanese myopic CNV patients in a real-world setting.
- 29 August 2018
- Published by Springer Nature in Eye
- Vol. 32 (12) , 1871-1878
Open AccessReal-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
Objectives The aim of this study was to obtain real-world clinical data on the safety and efficacy of ranibizumab treatment for myopic choroidal neovascularization (CNV) due to pathologic myopia. Methods This was a prospective, observational, post-marketing surveillance study in ranibizumab-naive Japanese patients with myopic CNV. Patients who initiated ranibizumab treatment were registered and prospectively observed over 12 months. Safety endpoints were the incidence of ocular and non-ocular adverse drug reactions (ADRs) and serious adverse events (SAEs). The efficacy endpoint included the average change in best-corrected visual acuity (BCVA) in logarithm of the minimal angle of resolution (logMAR) units (logMAR BCVA) from baseline to the last observation. Results Three hundred and eighteen patients were included in the safety analysis population. Of these 79.9% were female and the mean age was 65.5 years. The incidences of SAEs and ADRs were 0.6 and 0.3%, respectively. A total of 268 patients (84.0%) completed the 12-month study period. The mean (±SD) and median number of ranibizumab injections were 2.0 ± 1.5 and 1.0 during the 12-month study period, respectively. The number of ranibizumab injections received was one in 52.2% of patients and less than or equal to three in 89.2%. The mean change in logMAR BCVA from baseline to month 12 was −0.193, and the mean logMAR BCVA improved from 0.517 to 0.319 between baseline and month 12. Conclusions This study showed that ranibizumab is generally well tolerated, and that a minimum number of injections were necessary to produce a therapeutic effect in Japanese myopic CNV patients in a real-world setting.
- 1 March 2018
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 63, 92-106
Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia
- 1 March 2018
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 63, 92-106
Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia
- Top Cited Papers
- 1 May 2015
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 159 (5) , 877-883.e7
International Photographic Classification and Grading System for Myopic Maculopathy
- 1 May 2015
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 159 (5) , 877-883.e7
Top Cited PapersInternational Photographic Classification and Grading System for Myopic Maculopathy
- 1 August 2011
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 152 (2) , 256-265.e1
Long-term Development of Significant Visual Field Defects in Highly Myopic Eyes
- 1 August 2011
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 152 (2) , 256-265.e1
Long-term Development of Significant Visual Field Defects in Highly Myopic Eyes
- 21 April 2006
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 244 (11) , 1474-1479
Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia
To clarify prognostic factors of long-term visual outcome without treatment in patients with myopic choroidal neovascularization (CNV) and estimate a regression equation to predict visual acuity at 5 years after CNV onset.
- 21 April 2006
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 244 (11) , 1474-1479
Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia
To clarify prognostic factors of long-term visual outcome without treatment in patients with myopic choroidal neovascularization (CNV) and estimate a regression equation to predict visual acuity at 5 years after CNV onset.
- 1 August 2005
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 49 (4) , 306-311
Fundus Characteristics of High Myopia in Children
To evaluate the fundus characteristics of highly myopic eyes in children.
- 1 August 2005
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 49 (4) , 306-311
Fundus Characteristics of High Myopia in Children
To evaluate the fundus characteristics of highly myopic eyes in children.
- 28 July 2004
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 243 (1) , 13-19
Characteristics of patients with a favorable natural course of myopic choroidal neovascularization
To identify the characteristics of patients with myopic choroidal neovascularization (CNV) who had a favorable visual prognosis without treatment.
- 28 July 2004
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 243 (1) , 13-19
Characteristics of patients with a favorable natural course of myopic choroidal neovascularization
To identify the characteristics of patients with myopic choroidal neovascularization (CNV) who had a favorable visual prognosis without treatment.
- 1 December 2003
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 44 (12) , 5370-5375
Reduced Retinal Angiogenesis in MMP-2–Deficient Mice
Purpose. To study the putative role of endogenous matrix metalloproteinases (MMPs) in retinal neovascularization, an established mouse model was used to compare the retinal neovascularization observed in wild-type mice with that in mice without the MMP-2 or -9 genes. methods. C57Bl/6 (MMP-2+/+ and -9+/+), MMP-2–deficient (MMP-2−/−), and MMP-9–deficient (MMP-9−/−) mice were used. After oxygen-induced retinopathy was induced in the mice, their eyes were rapidly removed and frozen in optimal cutting temperature embedding compound. Sections were histochemically stained with specific markers for vascular cells and angiogenesis-related factors. The area of new retinal vessels was measured using image-analysis software and compared between groups. results. Retinal neovascularization was not significantly different between wild-type and MMP-9−/− mice. The MMP-2−/− mice had significantly less extraretinal neovascularization than did wild-type mice. The mean number of extraretinal neovascular buds per cross section was significantly lower in MMP-2−/− mice than in wild-type mice (P < 0.05). The expression of other angiogenesis-related factors, vascular endothelial growth factor and pigment epithelium-derived factor, was not different between wild-type and MMP-2−/− mice. conclusions. MMP-2 may be essential in the regulation of retinal neovascularization. Pharmacologic intervention using MMP inhibitors may be a future therapeutic approach for angiogenic retinal diseases.
- 1 December 2003
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 44 (12) , 5370-5375
Reduced Retinal Angiogenesis in MMP-2–Deficient Mice
Purpose. To study the putative role of endogenous matrix metalloproteinases (MMPs) in retinal neovascularization, an established mouse model was used to compare the retinal neovascularization observed in wild-type mice with that in mice without the MMP-2 or -9 genes. methods. C57Bl/6 (MMP-2+/+ and -9+/+), MMP-2–deficient (MMP-2−/−), and MMP-9–deficient (MMP-9−/−) mice were used. After oxygen-induced retinopathy was induced in the mice, their eyes were rapidly removed and frozen in optimal cutting temperature embedding compound. Sections were histochemically stained with specific markers for vascular cells and angiogenesis-related factors. The area of new retinal vessels was measured using image-analysis software and compared between groups. results. Retinal neovascularization was not significantly different between wild-type and MMP-9−/− mice. The MMP-2−/− mice had significantly less extraretinal neovascularization than did wild-type mice. The mean number of extraretinal neovascular buds per cross section was significantly lower in MMP-2−/− mice than in wild-type mice (P < 0.05). The expression of other angiogenesis-related factors, vascular endothelial growth factor and pigment epithelium-derived factor, was not different between wild-type and MMP-2−/− mice. conclusions. MMP-2 may be essential in the regulation of retinal neovascularization. Pharmacologic intervention using MMP inhibitors may be a future therapeutic approach for angiogenic retinal diseases.
- 28 November 2003
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 242 (2) , 114-119
Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia
To examine the influencing factors on the development of chorioretinal atrophy, which is the main cause of long-term visual decrease in myopic choroidal neovascularization (CNV), in a large series of highly myopic patients.
- 28 November 2003
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 242 (2) , 114-119
Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia
To examine the influencing factors on the development of chorioretinal atrophy, which is the main cause of long-term visual decrease in myopic choroidal neovascularization (CNV), in a large series of highly myopic patients.